Skip to main content
. 2021 Jan 7;13(2):192. doi: 10.3390/cancers13020192

Table 5.

SBRT versus Percutaneous Tumor Ablation (PTA): Multicentric retrospective studies and metanalysis.

Author Arm Number of Patients Tumor Control
(%)
p
(After PSM)
Complications Grade ≥ 3 (%)
Kim [39,40] SBRT 496 3-year LR 21.2 <0.001 (<0.001) 1.6
PTA 1568 3-year LR 27.9 2.6
Pan [41] SBRT 859 - 0.003 -
PTA 1873 - -
Lee [42] SBRT 779 2-year LC 84.5 0.431 0–11.4
PTA 1211 2-year LC 79.5 0–6.4

LR: Local Recurrence; LC; Local Control; PSM: Propensity Score Matching.